Interleukin-17A - A Potential Therapeutic Target in Chronic Lung Diseases

(E-pub Ahead of Print)

Author(s): Sadiya B Shaikh, Ashwini Prabhu, Yashodhar Prabhakar Bhandary*.

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets

Become EABM
Become Reviewer


Background: Interleukin-17A (IL-17A) is a pro-inflammatory cytokine that has gained a lot of attention because of its involvement in respiratory diseases. Interleukin-17 cytokine family includes six members, out of which, IL-17A participates towards the immune responses in allergy and inflammation. It also modulates the progression of respiratory disorders.

Objective: The present review is an insight into the involvement and contributions of the proinflammatory cytokine IL-17A in chronic respiratory diseases like idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary distress (COPD), asthma, pneumonia, obliterative bronchiolitis, lung cancer and many others.

Conclusion: IL-17A is a major regulator of inflammatory responses. In all the mentioned diseases, IL- 17A plays a prime role in inducing the diseases, whereas the lack of this pro-inflammatory cytokine reduces the severity of respective respiratory diseases. Thereby, this review suggests IL-17A as an instrumental target in chronic respiratory diseases.

Keywords: IL-17A, lung diseases, inflammation, cytokine, immune response, cell injury

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1871530319666190116115226
Price: $95

Article Metrics

PDF: 9